| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Glioblastoma is a primary malignant brain tumor and is an intractable disease with a poor prognosis. This study is a targeted therapeutic study against glioblastoma stem cells. We focused on the nuclear transcription factor RBPJ, which is an active indicator of Notch signaling. RBPJ expression was higher in glioblastoma tissue than in normal brain, and glioblastoma stem cells had higher RBPJ expression than differentiated glioblastoma cells. RBPJ inhibition of glioblastoma stem cells results in decreased cell proliferation and loss of stem cell phenotype. As a mechanism, we found that inhibition of RBPJ induced inhibition of the downstream factors interleukin 6 and STAT signal. Tumor reduction was also checked in animal studies. It suggested that inhibition of RBPJ is effective for the regulation of glioblastoma stem cells.
|
